Anesthesiology 1996, 85:1447–53.PubMedCrossRef 36. Saily VM, Petas A, Joutsi-Korhonen L, Taari K, Lassila R, Rannikko AS: Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation. Nepicastat ic50 Scand J Urol

2014, 48:153–159.PubMedCrossRef 37. Caine GJ, Stonelake PS, Lip GY, Kehoe ST: The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002, 4:465–73.PubMedCrossRefPubMedCentral 38. Glantzounis GK, Tsimaris I, Tselepis AD, Thomas C, Galaris DA, Tsimoyiannis EC: Alterations in plasma oxidative stress markers after laparoscopic operations of the upper and lower abdomen. Angiology 2005, 56:459–65.PubMedCrossRef 39. Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budaus L, Salomon G, Schlomm T, Perrotte P, Shariat SF, Montorsi F, Menon M, Graefen M, Karakiewicz PI: Venous thromboembolism after radical prostatectomy: the effect of surgical caseload. BJU

Int 2012, 110:828–33.PubMedCrossRef 40. Nguyen NT, Cronan M, Braley S, Rivers R, Wolfe BM: Duplex ultrasound assessment of femoral venous flow during laparoscopic and open gastric bypass. Surg Endosc 2003, 17:285–90.PubMedCrossRef 41. Nozuchi S, Mizobe T, Aoki H, Hiramatsu N, Kageyama K, Amaya F, Uemura K, Fujimiya T: Sevoflurane does not inhibit human platelet JPH203 cost aggregation induced by thrombin. Anesthesiology 2000, 92:164–70.PubMedCrossRef 42. Huang GS, Li CY, Hsu PC, Tsai CS, Lin TC, Wong CS: Sevoflurane anesthesia attenuates adenosine diphosphate-induced P-selectin Metalloexopeptidase expression and platelet-leukocyte conjugate formation. Anesth Analg

2004, 99:1121–6.PubMedCrossRef 43. Vasileiou I, Xanthos T, Koudouna E, Perrea D, Klonaris C, Katsargyris A, Papadimitriou L: Propofol: a review of its non-anaesthetic effects. Eur J Pharmacol 2009, 605:1–8.PubMedCrossRef Competing interests Sofra M, Antenucci A, Gallucci M, Mandoj C, Papalia R, Claroni C, Monteferrante I, Torregiani G, Gianaroli V, Sperduti I and Forastiere E: No interest declared. Authors’ contributions MS and EF contributed to conception and design of the study, acquisition, analysis and interpretation of data. AA, MG, CM and IS worked on the acquisition, analysis and interpretation of data. RP, CC, IM, GT and VG contributed to acquisition of data. All Authors were involved in drafting the manuscript or revising it critically for important intellectual content and gave final approval of the version to be published.”
“Background Bladder cancer is one of the most frequent malignancies in the world which includes several types of malignancy arising from the epithelial lining of the urinary bladder. Chromosomal anomalies, genetic polymorphisms, genetic and epigenetic alterations have been reported to be included in the tumorigenesis and progression of bladder cancer [1].